Found "Health Policies": 1,019 results
Sort by
Relevance

Using Financial Mechanisms to Develop a Quality and Outcomes Framework: Issues and Challenges

In the fiscal year of 2014, the National Health Security Office (NHSO) started to disburse its budget based on the Quality and Outcomes Framework (QOF). The QOF is a budget allocation mechanism that incentivizes hospitals to provide quality primary care and achieve results based on the defined indic

Your Friendly, Neighborhood GEAR Guide!

In 2015, a HITAP International Unit (HIU) survey identified the major challenges (both contextual and technical) to the conduct of rigorous economic evaluations for policymakers’ use in healthcare decision making. • From this study, HITAP created an online platform called the Guide to health Econ

Should high-cost bevacizumab be used for metastatic-colorectal cancer (mCRC) treatment in JKN in Indonesia?

Colorectal cancer is the third most common cancer in Indonesia with approximately 28,000 patients diagnosed each year. Without population-based screening, patients are often treated when they reach the advanced stage. Bevacizumab, a newly available high-cost treatment for metastatic colorectal ca

Cetuximab as an adjuvant therapy for metastatic colorectal cancer (mCRC): Does the high cost outweigh the benefit for saving patient’s life?

Cetuximab is provided for mCRC patients with positive KRAS wild type, and also head and neck cancer patients as indicated in the Indonesian National Drug Formulary. However, currently, it is also used for indications not specified in the National Drug Formulary. Adding cetuximab to chemothera

Would a rotavirus vaccination program for children under 5 years be cost-effective for Bhutan?

In many countries, rotavirus vaccination is the most cost-effective way to prevent rotavirus diarrhea. With this in mind, the Essential Medicines and Technology Division (EMTD) in collaboration with Health Intervention Technology Assessment Program (HITAP), Mahidol Oxford Research Unit (MORU), and P

Early HTA: A Guide for Developing Pulmonary Tuberculosis Cost-Effective Tests Fitting the Healthcare Needs

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (MTB) and represents a significant global health concern. Infectious agents can be easily spread through respiratory droplets, and TB patients face a significant risk of mortality. The traditional sputum-based TB

The Life Saving Drug Program: Australia’s pathway to high-cost drugs

Australia developed the Life-Saving Drugs Program (LSDP) in 1995 to complement the Pharmaceutical Benefits Scheme (PBS), expanding access to high-cost drugs for rare diseases (DRD). This program, funded and administered by the Department of Health and Aged Care, permitted sponsors (often pharmaceuti

Learning from Cancer Drug Fund (CDF) in England: A special reimbursement pathway for high-cost cancer drugs

The Cancer Drug Fund (CDF) is a dedicated source of funding in England for increasing patient access to high-cost cancer drugs, with a fixed budget of £340 million per year, operating since 2016. The CDF follows the appraisal by the National Institute of Health and Care Excellence (NICE) whic

FDA approves Ironwood constipation drug

The drug, linaclotide, will be sold under the brand name Linzess and carry a boxed warning that it should not be used in patients 16 or younger, the agency said.An estimated 63 million people suffer from chronic constipation, according to the National Institutes of Health. Additionally, an estimated
10 / Page